TIBER CREEK GROUP

Lobbying for AMGEN INC

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Apr 18, 2025

Lobbying activity 1

Medicare/Medicaid

Issues related to implementation of drug pricing and reimbursement for prescription drugs provision in Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D drug rebates.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.